Sanofi EBITDA 2010-2024 | SNY
Sanofi annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Sanofi EBITDA for the quarter ending September 30, 2024 was $4.204B, a 20.02% increase year-over-year.
- Sanofi EBITDA for the twelve months ending September 30, 2024 was $8.542B, a 17.11% decline year-over-year.
- Sanofi 2023 annual EBITDA was $14.78B, a 3.18% increase from 2022.
- Sanofi 2022 annual EBITDA was $14.324B, a 3.72% increase from 2021.
- Sanofi 2021 annual EBITDA was $13.81B, a 32.95% decline from 2020.
Sanofi Annual EBITDA
(Millions of US $) |
| 2023 |
$14,780 |
| 2022 |
$14,324 |
| 2021 |
$13,810 |
| 2020 |
$20,597 |
| 2019 |
$15,616 |
| 2018 |
$11,286 |
| 2017 |
$11,236 |
| 2016 |
$11,245 |
| 2015 |
$11,786 |
| 2014 |
$13,555 |
| 2013 |
$15,605 |
| 2012 |
$14,858 |
| 2011 |
$18,179 |
| 2010 |
$17,307 |
| 2009 |
$17,891 |
Sanofi Quarterly EBITDA
(Millions of US $) |
| 2024-09-30 |
$4,204 |
| 2024-06-30 |
$1,429 |
| 2024-03-31 |
$1,533 |
| 2023-12-31 |
$1,376 |
| 2023-09-30 |
$3,502 |
| 2023-06-30 |
$2,039 |
| 2023-03-31 |
$2,676 |
| 2022-12-31 |
$2,087 |
| 2022-09-30 |
$4,309 |
| 2022-06-30 |
$1,634 |
| 2022-03-31 |
$2,691 |
| 2021-09-30 |
$3,580 |
| 2021-03-31 |
$2,527 |
| 2020-09-30 |
$2,927 |
| 2020-03-31 |
$2,338 |
| 2019-09-30 |
$2,516 |
| 2019-03-31 |
$1,538 |
| 2018-03-31 |
$1,549 |
| 2017-12-31 |
$1,188 |
| 2017-09-30 |
$2,434 |
| 2017-06-30 |
$1,596 |
| 2017-03-31 |
$1,851 |
| 2016-12-31 |
$1,842 |
| 2016-09-30 |
$2,722 |
| 2016-06-30 |
$1,724 |
| 2016-03-31 |
$1,305 |
| 2015-09-30 |
$2,308 |
| 2015-06-30 |
$2,131 |
| 2014-06-30 |
$1,977 |
| 2013-06-30 |
$1,545 |
| 2012-06-30 |
$5,370 |
| 2012-03-31 |
$2,582 |
| 2011-12-31 |
$2,047 |
| 2011-09-30 |
$2,184 |
| 2011-06-30 |
$1,596 |
| 2011-03-31 |
$3,061 |
| 2010-12-31 |
$1,360 |
| 2010-09-30 |
$2,954 |
| 2010-06-30 |
$2,940 |
| 2010-03-31 |
$1,961 |
| 2009-12-31 |
$1,057 |
| 2009-09-30 |
$2,874 |
| 2009-06-30 |
$2,908 |
| 2009-03-31 |
$1,973 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$135.190B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
